Pipeline overview
CD20, 2nd generation ANKET®
Cancer
Phase 1/2
Preclinical
Phase 1
Phase 2
Phase 3
Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, High Risk-myelodysplasia
Phase 1/2
Preclinical
Phase 1
Phase 2
Phase 3
Multiple Myeloma
Phase 1/2
Preclinical
Phase 1
Phase 2
Phase 3
Cancer
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
undisclosed, multi-specific ANKET®
Cancer
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Nectin-4, Antibody Drug Conjugate
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
MICA/B, Antibody Drug Conjugate
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Cutaneous T Cell Lymphoma (Sézary Syndrome / Mycosis Fungoides)
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Peripheral T Cell Lymphoma
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Unresectable Stage III Non-small Cell Lung Cancer
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Neoadjuvant NSCLC, other
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Neoadjuvant Non-small Cell Lung Cancer
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Cancer (Solid Tumors)
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3